Chiffres en millions de dollars américains. L'exercice financier va de février à janvier.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Revenus
14
17
18
12
11
8
Croissance des revenus (H/H)
-18%
-6%
50%
9%
38%
-38%
Coût des ventes
6
8
9
6
4
3
Bénéfice brut
7
9
9
6
6
5
Vente, Général et Administration
15
16
19
18
17
15
Recherche et développement
3
3
5
3
2
2
Frais d'exploitation
18
19
24
21
20
17
Autres revenus (charges) non opérationnels
0
0
0
1
3
-2
Bénéfice avant impôts
-10
-11
-15
-15
-9
-15
Charge d'impôt sur le revenu
--
0
--
--
--
--
Bénéfice net
-10
-11
-15
-15
-10
-15
Croissance du bénéfice net
-9%
-27%
0%
50%
-33%
25%
Actions en circulation (diluées)
2.61
1.34
0.92
0.86
0.81
0.47
Variation des actions (H-H)
93%
45%
7%
6%
70%
49%
EPS (dilué)
-4.07
-8.42
-16.43
-17.45
-13.27
-33.14
Croissance du EPS
-50%
-49%
-6%
32%
-60%
-13%
Flux de trésorerie libre
-8
-9
-12
-14
-11
-8
Flux de trésorerie libre par action
--
--
--
--
--
--
Marge brute
50%
52.94%
50%
50%
54.54%
62.5%
Marge opérationnelle
-71.42%
-58.82%
-83.33%
-125%
-118.18%
-150%
Marge bénéficiaire
-71.42%
-64.7%
-83.33%
-125%
-90.9%
-187.5%
Marge du flux de trésorerie libre
-57.14%
-52.94%
-66.66%
-116.66%
-100%
-100%
EBITDA
-9
-9
-14
-15
-13
-12
Marge EBITDA
-64.28%
-52.94%
-77.77%
-125%
-118.18%
-150%
D&A pour le résultat opérationnel
1
1
1
0
0
0
EBIT
-10
-10
-15
-15
-13
-12
Marge EBIT
-71.42%
-58.82%
-83.33%
-125%
-118.18%
-150%
Taux d'imposition effectif
--
0%
--
--
--
--
Statistiques clés
Clôture préc.
$9.2
Prix d'ouverture
$9.2
Plage de la journée
$8.71 - $10.14
Plage de 52 semaines
$2.73 - $12.7
Volume
228.3K
Volume moyen
2.1M
BPA (TTM)
-5.57
Rendement en dividend
--
Capitalisation boursière
$33.4M
Qu’est-ce que EKSO ?
Ekso Bionics Holdings, Inc. engages in the provision of design, development, and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. The company is headquartered in San Rafael California, California and currently employs 61 full-time employees. The company went IPO on 2013-04-10. Its exoskeleton technology serves people with physical disabilities or impairments in both physical rehabilitation and mobility. The company operates as one segment with two markets: Enterprise Health and Personal Health. Its products include EksoNR, which is a wearable robotic exoskeleton designed for a rehabilitation setting; Ekso Indego Therapy is a modular, adjustable, lightweight, lower limb-powered exoskeleton; Ekso Indego Personal is a lower limb orthosis; Ekso Nomad is a power Knee Ankle Foot Orthosis, and Ekso EVO is a wearable upper body exoskeleton. The company enables individuals with neurological conditions affecting gait, including acquired brain injury (ABI) and spinal cord injury (SCI), to rehabilitate, stand and walk again. Additionally, the devices assist people with a variety of upper extremity disabilities and enable industrial employees to perform challenging repetitive tasks for extended periods.